source
- Precision strategies help de-risk rare disease therapy launchesCommercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…
- FDA Approves First Single-Dose Generic Treatment for InfluenzaThe U.S. Food and Drug Administration today approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in…fda press · 2mo ago↗ source
- FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose